WeberRJ, KaneSL, OrioloVA, SaulM, SkledarSJ, DastaJF.Impact of intensive care unit (ICU) drug use on hospital costs: A descriptive analysis, with recommendations for optimizing ICU pharmacotherapy. Crit Care Med. 2003;31-(1 suppl):S17–24.
2.
Kane-GillS, ReaRS, VerricoMM, WeberRJ.Adverse-drug-event rates for high-cost and high-use drugs in the intensive care unit. Am J Health Syst Pharm. 2006;63(19):1876–1881.
3.
Kane-GillSL, KirisciL, VerricoMM, RothschildJM.Analysis of risk factors for adverse drug events in critically ill patients. Crit Care Med. 2012;40(3):823–828.
4.
Kane-GillSL, JacobiJ, RothschildJM.Adverse drug events in intensive care units: Risk factors, impact, and the role of team care. Crit Care Med. 2010;38(6 suppl): S83–89.
5.
FarzaneganB, AlehashemM, BastaniM, BaniasadiS.Potential drug-drug interactions in cardiothoracic intensive care unit of a pulmonary teaching hospital [published online ahead of print November 5, 2014]. J Clin Pharmacol. doi:10.1002/jcph.421
6.
AhmedAH, GiriJ, KashyapR, Outcome of adverse events and medical errors in the intensive care unit: A systematic review and meta-analysis [published online ahead of print December 19, 2013]. Am J Med Qual.
7.
PreslaskiCR, LatI, MacLarenR, PostonJ.Pharmacist contributions as members of the multidisciplinary ICU team. Chest. 2013;144(5):1687–1695.
8.
MacLarenR, BondCA.Effects of pharmacist participation in intensive care units on clinical and economic outcomes of critically ill patients with thromboembolic or infarctionrelated events. Pharmacotherapy. 2009;29(7):761–768.
9.
KaneSL, WeberRJ, DastaJF.The impact of critical care pharmacists on enhancing patient outcomes. Intens Care Med. 2003;29(5):691–698.
